EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG announces appointment of
chairman of Management Board
17.10.2012 – 22:10
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- C.E.O. Interviews 17.10.2012 Ad hoc-Release according to § 15 WpHG SYGNIS Pharma AG announces appointment of chairman of Management Board Heidelberg, October 17, 2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) announces the appointment of Mrs. Pilar de la Huerta to the Management Board of the Company and her nomination as chairman of the Management Board (CEO) by the Supervisory Board subsequently to today's Shareholders' Meeting. **** end of ad hoc **** For further information please contact: SYGNIS Pharma AG Peter Willinger Co-CEO/CFO Tel: +49 6221 454 836 Email: {willinger@sygnis.de}[HYPERLINK: mailto:willinger@sygnis.de] ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### Further inquiry note: Michael Wolf Telefon: +49 (6221) 454 - 6 E-Mail: Michael.Wolf@sygnis.de end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1E9B74 indexes: CDAX, Prime All Share stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: English